Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 3.9%

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s share price traded down 3.9% on Thursday . The company traded as low as $36.02 and last traded at $36.50. 105,309 shares traded hands during trading, a decline of 76% from the average session volume of 435,331 shares. The stock had previously closed at $37.99.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Piper Sandler restated an "overweight" rating and set a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Needham & Company LLC restated a "buy" rating and set a $40.00 price objective on shares of Collegium Pharmaceutical in a research report on Thursday. Jefferies Financial Group restated a "hold" rating and set a $37.00 price objective (up previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. StockNews.com downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 29th. Finally, Truist Financial increased their price target on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a "buy" rating in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $39.00.

Collegium Pharmaceutical Stock Down 4.2 %

The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. The firm has a market capitalization of $1.19 billion, a P/E ratio of 30.84 and a beta of 1.03. The company's 50-day simple moving average is $36.58 and its two-hundred day simple moving average is $30.26.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The business had revenue of $149.75 million for the quarter, compared to the consensus estimate of $147.66 million. As a group, research analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 23,560 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $32.28, for a total value of $760,516.80. Following the completion of the sale, the executive vice president now directly owns 111,322 shares of the company's stock, valued at $3,593,474.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.69% of the company's stock.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. increased its stake in shares of Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company's stock worth $66,938,000 after purchasing an additional 883,380 shares in the last quarter. Natixis Advisors L.P. grew its stake in Collegium Pharmaceutical by 152.9% during the third quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company's stock valued at $1,215,000 after acquiring an additional 32,865 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in Collegium Pharmaceutical by 32.7% during the third quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company's stock valued at $6,116,000 after acquiring an additional 67,439 shares in the last quarter. Barclays PLC grew its stake in Collegium Pharmaceutical by 16.9% during the third quarter. Barclays PLC now owns 39,593 shares of the specialty pharmaceutical company's stock valued at $886,000 after acquiring an additional 5,713 shares in the last quarter. Finally, Ritholtz Wealth Management purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at $286,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.